These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8048778)

  • 1. Effect of rate of administration of recombinant tissue plasminogen activator on efficacy of coronary thrombolysis.
    Prewitt RM; Gu S; Schick U; Ducas J
    Angiology; 1994 Aug; 45(8):687-94. PubMed ID: 8048778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coronary thrombolysis. Comparative effects of intracoronary administration of recombinant tissue plasminogen activator and urokinase.
    Gu S; Ducas J; Patton JN; Greenberg D; Prewitt RM
    Chest; 1992 Jun; 101(6):1684-90. PubMed ID: 1600792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs intravenous administration.
    Gu SA; Ducas J; Wolfe K; Patton JN; Prewitt RM
    Chest; 1991 Jul; 100(1):201-6. PubMed ID: 1905615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous administration of recombinant tissue plasminogen activator. Optimizing the rate of coronary thrombolysis.
    Prewitt RM; Gu S; Schick U; Ducas J
    Chest; 1995 Apr; 107(4):1146-51. PubMed ID: 7705128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing coronary thrombolysis with i.v. administration of recombinant tissue plasminogen activator. Single bolus vs double bolus vs front-loading.
    Prewitt RM; Schick U; Ducas J
    Chest; 1996 Feb; 109(2):510-5. PubMed ID: 8620730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked systemic hypotension depresses coronary thrombolysis induced by intracoronary administration of recombinant tissue-type plasminogen activator.
    Prewitt RM; Gu S; Garber PJ; Ducas J
    J Am Coll Cardiol; 1992 Dec; 20(7):1626-33. PubMed ID: 1452937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA; Lee P; Rios G; Kottke-Marchant K; Topol EJ
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An increase in low aortic pressure increases coronary artery flow and coronary thrombolysis induced by intravenous administration of recombinant tissue plasminogen activator.
    Garber PJ; Gu S; Ducas J; Schick U; Prewitt RM
    J Crit Care; 1995 Mar; 10(1):1-6. PubMed ID: 7757138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjunctive therapy with low molecular weight heparin with recombinant tissue-type plasminogen activator causes sustained reflow in canine coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Khan S; Mehta JL
    Am Heart J; 1992 Aug; 124(2):280-8. PubMed ID: 1322029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrograde coronary venous administration of recombinant tissue-type plasminogen activator: a unique and effective approach to coronary artery thrombolysis.
    Miyazaki A; Tadokoro H; Drury JK; Rydén L; Haendchen RV; Corday E
    J Am Coll Cardiol; 1991 Aug; 18(2):613-20. PubMed ID: 1906906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
    Gurbel PA; Anderson RD; MacCord CS; Scott H; Komjathy SF; Poulton J; Stafford JL; Godard J
    Circulation; 1994 Jan; 89(1):361-5. PubMed ID: 8281671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early intravenous administration of metoprolol enhances myocardial salvage by thrombolysis with recombinant tissue-type plasminogen activator after thrombotic coronary artery occlusion in the dog by improvement of the collateral blood flow to the area at risk.
    Zmudka K; Aubert A; Dubiel J; Vanhaecke J; Flameng W; Kaczmarek J; De Geest H
    J Am Coll Cardiol; 1994 May; 23(6):1499-504. PubMed ID: 8176113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombolytic therapy in canine pulmonary embolism. Comparative effects of urokinase and recombinant tissue plasminogen activator.
    Prewitt RM; Hoy C; Kong A; Gu SA; Greenberg D; Cook R; Chan SM; Ducas J
    Am Rev Respir Dis; 1990 Feb; 141(2):290-5. PubMed ID: 2105682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H
    Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
    Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
    Jpn J Pharmacol; 1993 Nov; 63(3):319-25. PubMed ID: 8107325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of hydralazine and increased cardiac output on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
    Prewitt RM; Downes AM; Gu SA; Chan SM; Ducas J
    Chest; 1991 Mar; 99(3):708-14. PubMed ID: 1899825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of low-molecular-weight heparin on recombinant tissue plasminogen activator-induced thrombolysis in canine pulmonary embolism.
    Werier J; Ducas J; Gu S; Chan SM; Prewitt RM
    Chest; 1991 Aug; 100(2):464-9. PubMed ID: 1650681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure of prostacyclin analog iloprost to sustain coronary blood flow after recombinant tissue-type plasminogen-induced thrombolysis in dogs.
    Nichols WW; Nicolini FA; Khan S; Saldeen TG; Mehta JL
    Am Heart J; 1993 Aug; 126(2):285-92. PubMed ID: 7687816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.
    Susawa T; Yui Y; Hattori R; Takahashi M; Aoyama T; Takatsu Y; Sakaguchi K; Yui N; Kawai C
    Jpn Circ J; 1987 Apr; 51(4):431-5. PubMed ID: 2441082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.